

Paradigm Biopharmaceuticals Ltd

22:36 09 Sep 2019

Paradigm Biopharmaceuticals gets FDA clearance for investigational new drug application

Paradigm Biopharmaceuticals Ltd (ASX:PAR) has confirmed that its first Investigational New Drug (IND) application (filed in August 2019) has been cleared by the US FDA within the 30-day review period.

The company submitted an Expanded Access IND for pentosan polysulfate sodium (PPS) for the treatment of about 10 patients with pain associated with knee osteoarthritis (OA) with concurrent bone marrow lesions where patients have failed to respond to standard of care.

Expanded access, also called 'compassionate use', provides a pathway for patients to gain access to investigational drugs, biologics, and medical devices used to diagnose, monitor, or treat patients with serious diseases or conditions for which there are no comparable or satisfactory therapy options available.

Knee osteoarthritis pain

The physician treating the patients, under the IND, is an ex-NFL player with the Green Bay Packers.

Since his retirement from the NFL, Dr Michels, has worked primarily with sportspeople such as retired NFL players.

A major risk factor for osteoarthritis is joint injury. Knee injury is a common injury amongst NFL players.

Price: 3.36

Market Cap: \$653.44 m

1 Year Share Price Graph



November 2018 May 2019 November 20

Share Information

Code: PAR

Listing: ASX

52 week High Low
3.38 0.839883

Sector: Pharma & Biotech

Website: www.paradigmbiopharma.com

Company Synopsis:

Paradigm Biopharmaceuticals Ltd (ASX:PAR) is listed on the Australian Securities Exchange.

action@proactiveinvestors.com

In males under the age of 60, arthritis is over 3 times more prevalent in retired NFL players than in the general U.S. population

Potential treatment for a serious chronic disease

Paradigm chief executive officer Paul Rennie said: "We are very pleased to announce that Paradigm's Expanded Access IND has been cleared by the US

FDA within the 30-day review period.

"This clearance demonstrates the need for effective and safe therapies for the serious chronic disease of osteoarthritis. It also provides validation of the Paradigm dossier which contained information about our non-clinical and toxicology, our manufacturing and our clinical data and data about the previous human experience with the drug".

Rennie added: "FDA clearance means validation of Paradigm's

- safety data;
- the finished product's quality; and
- confirmation of an unmet medical need".

"Paradigm has also been able to demonstrate it now has very experienced staff with regulatory, manufacturing and clinical expertise, which is important as we plan to have an additional two pre-IND submissions with the US FDA before the end of CY 2019".

"Dr Michels will be treating people with osteoarthritis who have failed to respond to standard of care medications. Paradigm now looks forward to the completion of the Expanded Access Programme and reporting on those results in the months ahead".

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Paradigm Biopharmaceuticals Ltd named herein, including the promotion by the Company of Paradigm Biopharmaceuticals Ltd in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).